NATCO Pharma has won a landmark legal battle to launch a generic version of Risdiplam, a drug for Spinal Muscular Atrophy (SMA), a severe muscle disorder in infants. Shares of NATCO Pharma Ltd ended higher on Thursday, October 9, by 0.67% at ₹814.45 on NSE.
